Phospho-FUNDC1 (Ser17) antibody - #AF0001

Fig. 6 NTRK1 silencing might suppress mitophagy in mouse neurons through the inactivation of the AMPK/ULK1/FUNDC1 pathway. A, B WB revealed that O304 treatment abrogated the suppression effect of NTRK1 knockdown on the activity of the AMPK/ULK1/FUNDC1 pathway in mouse neurons. n = 3. C, D WB also indicated that O304 treatment counteracted the suppression effect of NTRK1 silencing on mitophagy in mouse neurons. n = 3. E, F The results of TOMM20/LC3-II fluorescence staining revealed that the O304 treatment reversed the suppression effect of NTRK1 knockdown on the expression of Parkin in mouse neuronmitochondria. n = 3.

Figure 1 Expressions of inflammatory cytokines, HIF-1α and FUNDC1 in healthy and pulpitis tissues. (A) mRNA expression of IL-1β, IL-6, IL-8 and TNF-α in human healthy and pulpitis tissues. mRNA expression of (B) HIF-1α and (C) FUNDC1 in human healthy and pulpitis tissues. (D) Representative immunostaining images of HIF-1α and FUNDC1 in human healthy or inflamed dental pulp tissues. Scale bars are 100 and 25 µm, respectively. Results are presented as the means ± SD from ≥ three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 vs. healthy. HIF-1α, hypoxia-inducible factor-1α; FUNDC1, FUN14 domain-containing 1.

Fig. 2 hUC-MSC improved the ovarian function of POF rats. A The percentage of each stage in the estrus cycle (the asterisk indicates there are significances in that group by comparing to the other two groups). The serum AMH (B), E2 (C), FSH (D), and LH (E) levels. F Ki67 expression in ovarian GCs; scale bar: 100 μm. G The Western blotting images and quantitation of functional protein expression in GCs. H The fertility and litter size.

Figure 6 Effects of Mo and/or Cd on immunofluorescence of LC3, mitophagy-related mRNA and protein expression levels. (A) The mRNA levels of FUNDC1, LC3A, LC3B and PGAM5. (B) The western blot results of FUNDC1, p-FUNDC1 and LC3. (C) The quantification of FUNDC1, p-FUNDC1 (Ser17) and LC3II/LC3I protein levels. (D) Immunofluorescence co-location of COX IV and LC3 at day 50. In the images, the nucleus staining is shown in blue, COX IV staining is shown in green, LC3 staining is shown in red, and the signals of colocalization are shown in merged images. (E) Pearson coefficient of the colocalization of COX IV and LC3. Data are expressed as means ± SD (n = 6). “*” indicates significant difference compared to the corresponding control (*P < 0.05, **P < 0.01). “#” indicates statistically significant difference between corresponding groups (#P < 0.05, ##P < 0.01).

Figure 6 The effects of MOX on FUNDC1 pathway. (A) The expression levels of ULK1, PGAM5, FUNDC1, p-FUNDC1 and GAPDH. (B) ULK1 relative to GAPDH, (C) PGAM5 relative to GAPDH, (D) FUNDC1 relative to GAPDH. (E) p-FUNDC1 relative to GAPDH. (F) ULK mRNA levels. (G) PGAM5 mRNA levels. (H) FUNDC1 mRNA levels. **P<0.05 vs. C group and #P<0.05 vs. DOX group. Protein levels were measured by western blotting. ULK1, PGAM5 and FUNDC1 mRNA levels were measured by RT-qPCR. Data are mean ± standard deviation from five independent experiments (n=13-20). MOX moxibustion; FUNDC1, FUN14 domain-containing protein 1; ULK1, Unc-51 Like Autophagy Activating Kinase 1; PGAM5, phosphoglycerate mutase family member 5; p-, phosphorylated; DOX, doxorubicin; BEN, benazepril C, control.